Generics
22 January 2026 A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.
21 January 2026
15 January 2026
9 December 2025
4 December 2025
23 September 2025
Latest Features
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
Supplementary Protection Certificate rules interpreted in different ways have left the EU’s generic and biosimilar industries hungry for clarity, explains Jiri Slavik of Adalvo.
Generics
While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.
Asia
Five cases in which preliminary injunctions were granted are examined by Takanori Abe of Abe & Partners.
Biotechnology
The Australian government has made numerous claims for damages against patentees for savings forgone when an interlocutory/preliminary injunction delays a generic's launch but the patent is invalidated or there is a finding of non-infringement.
Generics
Generic drug makers are watching two cases that will determine whether pharmaceutical firms can deduct—rather than capitalise—legal fees for defending against patent infringement suits, say Carina Federico and Anne Li of Crowell & Moring.
Americas
Certain problems with the patent opposition process need to be addressed in order to protect patent owners, say Alejandro Luna and Luz Elena Elias of Olivares.
Africa
Government-led schemes to incentivise patents are leading to delays and prejudice against legitimate applicants. Tyron Grant of Spoor and Fisher explains how South Africa is tackling the problem.
More News
18 September 2025 A UPC Court of Appeal decision establishes a new benchmark for what constitutes imminent infringement in pharmaceutical patent litigation, particularly regarding generics’ pre-launch preparations, writes Mike Gruber of Carpmaels & Ransford.
2 September 2025 A High Court decision clarifies how cross-undertakings work in patent disputes, rejecting claims for exceptional remedies beyond compensation.
20 August 2025 The Japanese pharma company has defended a key patent for a treatment that achieved record 2024 sales of over $6 billion—but a patent cliff looms.
23 July 2025 Court of Appeal backs Astellas in UK patent fight over prostate cancer drug | Generics’ challenge fails as judges warn on expert evidence and hindsight bias | Court urges caution when instructing expert witnesses in obviousness cases.
16 July 2025 Pharma giant wins preliminary injunction ‘in public interest’ regarding a generic of its Selenious Acid Injection | Judge finds infringement by pharma company Eugia of two Orange Book patents.
15 July 2025 After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more.
8 July 2025 German and Finnish pharma giants sue Indian rival in Delaware court | Dispute centres on generic bid for prostate cancer blockbuster | Suit follows leadership shakeup at Bayer.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox